Loading clinical trials...
Loading clinical trials...
Targeting Myeloid-Derived Suppressor Cells in Patients With Recurrent/Progressive Grade 4 Glioma: Phase 1 Trial of Sitagliptin
Conditions
Interventions
Sitagliptin
Bevacizumab
Locations
1
United States
University of Iowa Health Care
Iowa City, Iowa, United States
Start Date
May 31, 2026
Primary Completion Date
May 1, 2029
Completion Date
May 1, 2030
Last Updated
April 21, 2026
NCT07539441
NCT04065776
NCT03206060
NCT05636618
NCT03050268
NCT07243470
Lead Sponsor
Kailin Yang, MD, PhD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions